Cargando…

Quantitative immunohistochemical assay with novel digital immunostaining for comparisons of PD-L1 antibodies

One obstacle in diagnostic pathology is the harmonization of one drug-one diagnostic tests for programmed death ligand-1 (PD-L1). There are many challenges in accurate comparisons of diagnostic tests, such as differences in the titer of each antibody, detection system and dynamic range of visualizat...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujisawa, Takuo, Tsuta, Koji, Yanagimoto, Hiroaki, Yagi, Masao, Suzuki, Kensuke, Nishikawa, Kenji, Takahashi, Masaru, Okada, Hisatake, Nakano, Yasushi, Iwai, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6388504/
https://www.ncbi.nlm.nih.gov/pubmed/30847180
http://dx.doi.org/10.3892/mco.2019.1801
_version_ 1783397777396465664
author Fujisawa, Takuo
Tsuta, Koji
Yanagimoto, Hiroaki
Yagi, Masao
Suzuki, Kensuke
Nishikawa, Kenji
Takahashi, Masaru
Okada, Hisatake
Nakano, Yasushi
Iwai, Hiroshi
author_facet Fujisawa, Takuo
Tsuta, Koji
Yanagimoto, Hiroaki
Yagi, Masao
Suzuki, Kensuke
Nishikawa, Kenji
Takahashi, Masaru
Okada, Hisatake
Nakano, Yasushi
Iwai, Hiroshi
author_sort Fujisawa, Takuo
collection PubMed
description One obstacle in diagnostic pathology is the harmonization of one drug-one diagnostic tests for programmed death ligand-1 (PD-L1). There are many challenges in accurate comparisons of diagnostic tests, such as differences in the titer of each antibody, detection system and dynamic range of visualization. Our previously developed digital immunostaining technique is highly sensitive and quantitative with the ability to quantify particles that bind in a one-to-one fashion with antibody in each cell. Determining the differences in the titer of each antibody with digital immunostaining may be beneficial for future harmonized analysis. To demonstrate the accuracy of digital immunostaining, the present study compared the number of particles with ELISA and nCounter data from five cell lines. NCI-H460 exhib-ited the highest level of PD-L1 protein, followed by A549, PC-3, NCI-H1299, and NCI-H446 cells. In addition, the PD-L1 mRNA values determined by nCounter corresponded with the order of the protein levels determined by ELISA. The present study revealed that digital immunostaining for PD-L1 was highly associated with ELISA and nCounter data. Among the four antibodies tested, the titer of all but SP142 coincided with ELISA and nCounter data. These results indicated that our digital immunostaining technique may be beneficial for future harmonized analysis.
format Online
Article
Text
id pubmed-6388504
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-63885042019-03-07 Quantitative immunohistochemical assay with novel digital immunostaining for comparisons of PD-L1 antibodies Fujisawa, Takuo Tsuta, Koji Yanagimoto, Hiroaki Yagi, Masao Suzuki, Kensuke Nishikawa, Kenji Takahashi, Masaru Okada, Hisatake Nakano, Yasushi Iwai, Hiroshi Mol Clin Oncol Articles One obstacle in diagnostic pathology is the harmonization of one drug-one diagnostic tests for programmed death ligand-1 (PD-L1). There are many challenges in accurate comparisons of diagnostic tests, such as differences in the titer of each antibody, detection system and dynamic range of visualization. Our previously developed digital immunostaining technique is highly sensitive and quantitative with the ability to quantify particles that bind in a one-to-one fashion with antibody in each cell. Determining the differences in the titer of each antibody with digital immunostaining may be beneficial for future harmonized analysis. To demonstrate the accuracy of digital immunostaining, the present study compared the number of particles with ELISA and nCounter data from five cell lines. NCI-H460 exhib-ited the highest level of PD-L1 protein, followed by A549, PC-3, NCI-H1299, and NCI-H446 cells. In addition, the PD-L1 mRNA values determined by nCounter corresponded with the order of the protein levels determined by ELISA. The present study revealed that digital immunostaining for PD-L1 was highly associated with ELISA and nCounter data. Among the four antibodies tested, the titer of all but SP142 coincided with ELISA and nCounter data. These results indicated that our digital immunostaining technique may be beneficial for future harmonized analysis. D.A. Spandidos 2019-03 2019-01-17 /pmc/articles/PMC6388504/ /pubmed/30847180 http://dx.doi.org/10.3892/mco.2019.1801 Text en Copyright: © Fujisawa et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Fujisawa, Takuo
Tsuta, Koji
Yanagimoto, Hiroaki
Yagi, Masao
Suzuki, Kensuke
Nishikawa, Kenji
Takahashi, Masaru
Okada, Hisatake
Nakano, Yasushi
Iwai, Hiroshi
Quantitative immunohistochemical assay with novel digital immunostaining for comparisons of PD-L1 antibodies
title Quantitative immunohistochemical assay with novel digital immunostaining for comparisons of PD-L1 antibodies
title_full Quantitative immunohistochemical assay with novel digital immunostaining for comparisons of PD-L1 antibodies
title_fullStr Quantitative immunohistochemical assay with novel digital immunostaining for comparisons of PD-L1 antibodies
title_full_unstemmed Quantitative immunohistochemical assay with novel digital immunostaining for comparisons of PD-L1 antibodies
title_short Quantitative immunohistochemical assay with novel digital immunostaining for comparisons of PD-L1 antibodies
title_sort quantitative immunohistochemical assay with novel digital immunostaining for comparisons of pd-l1 antibodies
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6388504/
https://www.ncbi.nlm.nih.gov/pubmed/30847180
http://dx.doi.org/10.3892/mco.2019.1801
work_keys_str_mv AT fujisawatakuo quantitativeimmunohistochemicalassaywithnoveldigitalimmunostainingforcomparisonsofpdl1antibodies
AT tsutakoji quantitativeimmunohistochemicalassaywithnoveldigitalimmunostainingforcomparisonsofpdl1antibodies
AT yanagimotohiroaki quantitativeimmunohistochemicalassaywithnoveldigitalimmunostainingforcomparisonsofpdl1antibodies
AT yagimasao quantitativeimmunohistochemicalassaywithnoveldigitalimmunostainingforcomparisonsofpdl1antibodies
AT suzukikensuke quantitativeimmunohistochemicalassaywithnoveldigitalimmunostainingforcomparisonsofpdl1antibodies
AT nishikawakenji quantitativeimmunohistochemicalassaywithnoveldigitalimmunostainingforcomparisonsofpdl1antibodies
AT takahashimasaru quantitativeimmunohistochemicalassaywithnoveldigitalimmunostainingforcomparisonsofpdl1antibodies
AT okadahisatake quantitativeimmunohistochemicalassaywithnoveldigitalimmunostainingforcomparisonsofpdl1antibodies
AT nakanoyasushi quantitativeimmunohistochemicalassaywithnoveldigitalimmunostainingforcomparisonsofpdl1antibodies
AT iwaihiroshi quantitativeimmunohistochemicalassaywithnoveldigitalimmunostainingforcomparisonsofpdl1antibodies